ES2334260T3 - Procedimientos para la preparacion de la forma i cristalina de clorhidrato de cinacalcet. - Google Patents

Procedimientos para la preparacion de la forma i cristalina de clorhidrato de cinacalcet. Download PDF

Info

Publication number
ES2334260T3
ES2334260T3 ES06771215T ES06771215T ES2334260T3 ES 2334260 T3 ES2334260 T3 ES 2334260T3 ES 06771215 T ES06771215 T ES 06771215T ES 06771215 T ES06771215 T ES 06771215T ES 2334260 T3 ES2334260 T3 ES 2334260T3
Authority
ES
Spain
Prior art keywords
cinacalcet
hours
hydrochloride
solvent
cinacalcet hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06771215T
Other languages
English (en)
Spanish (es)
Inventor
Revital Lifshitz-Liron
Sharon Avhar-Maydan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Application granted granted Critical
Publication of ES2334260T3 publication Critical patent/ES2334260T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82—Purification; Separation; Stabilisation; Use of additives
    • C07C209/84—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82—Purification; Separation; Stabilisation; Use of additives
    • C07C209/90—Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Catalysts (AREA)
ES06771215T 2005-05-23 2006-05-23 Procedimientos para la preparacion de la forma i cristalina de clorhidrato de cinacalcet. Expired - Lifetime ES2334260T3 (es)

Applications Claiming Priority (33)

Application Number Priority Date Filing Date Title
US68415205P 2005-05-23 2005-05-23
US684152P 2005-05-23
US69698105P 2005-07-05 2005-07-05
US696981P 2005-07-05
US69711105P 2005-07-06 2005-07-06
US697111P 2005-07-06
US69861305P 2005-07-11 2005-07-11
US698613P 2005-07-11
US70123205P 2005-07-20 2005-07-20
US701232P 2005-07-20
US70291805P 2005-07-26 2005-07-26
US702918P 2005-07-26
US70691005P 2005-08-09 2005-08-09
US706910P 2005-08-09
US73005005P 2005-10-24 2005-10-24
US730050P 2005-10-24
US73208305P 2005-10-31 2005-10-31
US732083P 2005-10-31
US73300805P 2005-11-02 2005-11-02
US733008P 2005-11-02
US73466905P 2005-11-07 2005-11-07
US734669P 2005-11-07
US73512605P 2005-11-08 2005-11-08
US735126P 2005-11-08
US73882705P 2005-11-21 2005-11-21
US738827P 2005-11-21
US74178705P 2005-12-01 2005-12-01
US741787P 2005-12-01
US75091005P 2005-12-15 2005-12-15
US750910P 2005-12-15
US79480406P 2006-04-24 2006-04-24
US794804P 2006-04-24
PCT/US2006/020304 WO2006127933A1 (en) 2005-05-23 2006-05-23 Processes for preparing cinacalcet hydrochloride crystal form i

Publications (1)

Publication Number Publication Date
ES2334260T3 true ES2334260T3 (es) 2010-03-08

Family

ID=37101358

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06771215T Expired - Lifetime ES2334260T3 (es) 2005-05-23 2006-05-23 Procedimientos para la preparacion de la forma i cristalina de clorhidrato de cinacalcet.

Country Status (12)

Country Link
US (2) US7294735B2 (enExample)
EP (3) EP1805135A2 (enExample)
JP (3) JP4638491B2 (enExample)
KR (2) KR20070088485A (enExample)
CN (1) CN101180261A (enExample)
AT (1) ATE445587T1 (enExample)
CA (2) CA2605736A1 (enExample)
ES (1) ES2334260T3 (enExample)
IL (2) IL185108A0 (enExample)
MX (1) MX2007000983A (enExample)
TW (1) TW200716512A (enExample)
WO (2) WO2006127932A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415501B2 (en) * 2006-03-23 2013-04-09 Amgen, Inc. Methods and compositions for making and using polymorphs of cinacalcet
US20090197970A1 (en) * 2006-06-27 2009-08-06 Sandoz Ag Crystalline form of cinacalcet
WO2008000422A1 (en) * 2006-06-27 2008-01-03 Sandoz Ag Amorphous form of cinacalcet
EP1913941A1 (en) * 2006-10-19 2008-04-23 Sandoz AG Polymorphic forms and solvates of Cinacalcet hydrochloride
MX2009002335A (es) * 2006-09-01 2009-03-20 Teva Pharma Composiciones solidas de un compuesto activo receptor de calcio.
WO2008058236A2 (en) * 2006-11-08 2008-05-15 Dr. Reddy's Labortories, Ltd. Methods for preparing cinacalcet hydrochloride
US20080146845A1 (en) * 2006-11-20 2008-06-19 Boaz Gome Process for preparing Cinacalcet
EP2170805B1 (en) * 2007-06-21 2016-03-16 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
ITMI20071261A1 (it) 2007-06-22 2008-12-23 Dipharma Francis Srl Procedimento per la preparazione di cinacalcet
WO2009025792A2 (en) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
CN101932549A (zh) 2007-09-18 2010-12-29 麦迪凯姆股份公司 制备西那卡塞盐酸盐的改进方法
JP5406194B2 (ja) * 2007-10-01 2014-02-05 アセンタ セラピューティックス インコーポレイティッド Ｒ−ゴシポールｌ−フェニルアラニノールジエナミンを調製するための方法
EP2300415A2 (en) * 2008-05-05 2011-03-30 Medichem, S.A. Process for controlling the particle size of a 3-(trifluoromethyl)phenyl¨-1-aminopropane derivative
EP2321256B1 (en) * 2008-06-18 2014-11-12 ERREGIERRE S.p.A. Process for the synthesis of cinacalcet hydrochloride
WO2010015935A2 (en) * 2008-08-06 2010-02-11 Actavis Group Ptc Ehf Unsaturated cinacalcet salts and processes for preparing cinacalcet hydrochloride
US20110318417A1 (en) * 2008-12-08 2011-12-29 Actavis Group Ptc Ehf Highly pure cinacalcet or a pharmaceutically acceptable salt thereof
EP2398763A2 (en) 2009-02-19 2011-12-28 ZaCh System S.p.A. Process for preparing cinacalcet hydrochloride
US8575393B2 (en) 2009-03-05 2013-11-05 Cipla Limited Process for the preparation of cinacalcet and salts thereof, and intermediates for use in the process
WO2010128388A2 (en) 2009-05-08 2010-11-11 Aurobindo Pharma Limited An improved process for the preparation of intermediate compounds useful for the preparation of cinacalcet
CA2769659C (en) 2009-09-10 2017-10-24 Zach System S.P.A. Process for preparing cinacalcet
US8722732B2 (en) 2009-09-29 2014-05-13 Nektar Therapeutics Oligomer-calcimimetic conjugates and related compounds
IT1396623B1 (it) 2009-11-26 2012-12-14 Dipharma Francis Srl Procedimento per la preparazione di cinacalcet e suoi intermedi
CZ303627B6 (cs) * 2011-11-25 2013-01-16 Zentiva, K.S. Zpusob výroby Cinacalcetu
CN103450027B (zh) 2012-05-29 2015-07-29 上海京新生物医药有限公司 盐酸西那卡塞的制备方法
FR2995307A1 (fr) 2012-09-07 2014-03-14 Prod Chim Auxiliaires Et De Synthese Procede de preparation du cinacalcet et de ses sels pharmaceutiquement acceptables
CN103739500B (zh) * 2012-12-27 2016-03-23 国药一心制药有限公司 一种盐酸西那卡塞的合成与精制方法
CN103193655B (zh) * 2013-04-15 2015-06-24 山东新华制药股份有限公司 盐酸西那卡塞晶型ⅰ的制备方法
CN104512864B (zh) * 2013-09-30 2017-08-22 中国石油化工股份有限公司 一种低温脱除微量碳氧化物的方法
EP3578546A1 (en) 2013-11-15 2019-12-11 Akebia Therapeutics Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
BR102015025502B1 (pt) * 2015-04-30 2022-06-21 Aegerion Pharmaceuticals, Inc Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição
CN104892428A (zh) * 2015-06-05 2015-09-09 南京辰逸生物科技有限公司 一种盐酸西那卡塞的制备方法
CN106610404B (zh) * 2015-10-21 2019-01-15 华仁药业股份有限公司 采用hplc法检测盐酸西那卡塞同分异构体的方法
CN105439818B (zh) * 2015-12-31 2017-11-28 苏州汇和药业有限公司 一种西那卡塞中间体3‑(3‑三氟甲基苯基)丙醇的合成方法
CN107879939A (zh) * 2016-09-30 2018-04-06 上海天慈生物谷生物工程有限公司 一种制备 n‑((1r)‑1‑(1‑萘基)乙基)‑3‑(3‑(三氟甲基)苯基)丙‑1‑胺盐酸盐的方法
KR20200022712A (ko) 2018-08-23 2020-03-04 주식회사 오스코텍 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법
CN109096119B (zh) * 2018-10-29 2019-10-25 江苏永安制药有限公司 一种制备盐酸西那卡塞的方法
CN110041206B (zh) * 2019-04-29 2021-10-19 梯尔希（南京）药物研发有限公司 一种西那卡塞杂质的制备方法
CN111153832B (zh) * 2020-01-20 2022-02-25 广州九植医药科技有限公司 一种西那卡塞杂质的制备方法
WO2025003974A1 (en) * 2023-06-30 2025-01-02 Chong Kun Dang Pharmaceutical Corp. New preparation method of compound and new crystalline form

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966988A (en) * 1989-02-17 1990-10-30 Chevron Research Company Process for preparing acetonitrile 3-trifluoromethyl benzene
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP1203761B1 (en) * 1994-10-21 2005-01-19 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
US5648541A (en) * 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
DK0907631T3 (da) * 1996-05-01 2003-09-22 Nps Pharma Inc Uorganiske ionreceptoraktive forbindelser
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
ES2401769T5 (es) * 2003-09-12 2020-07-01 Amgen Inc Formulación de disolución rápida de cinacalcet HCl

Also Published As

Publication number Publication date
WO2006127933A8 (en) 2007-08-30
JP2010280715A (ja) 2010-12-16
JP4638491B2 (ja) 2011-02-23
EP1975150A1 (en) 2008-10-01
WO2006127933A1 (en) 2006-11-30
MX2007000983A (es) 2007-04-16
KR20070083471A (ko) 2007-08-24
ATE445587T1 (de) 2009-10-15
US20070060645A1 (en) 2007-03-15
IL185494A0 (en) 2008-01-06
US20070099998A1 (en) 2007-05-03
WO2006127932A2 (en) 2006-11-30
EP1883618B1 (en) 2009-10-14
CN101180261A (zh) 2008-05-14
EP1883618A1 (en) 2008-02-06
EP1805135A2 (en) 2007-07-11
WO2006127932A3 (en) 2007-02-01
IL185108A0 (en) 2007-12-03
TW200716512A (en) 2007-05-01
CA2606099A1 (en) 2006-11-30
JP2008507566A (ja) 2008-03-13
US7294735B2 (en) 2007-11-13
CA2605736A1 (en) 2006-11-30
US7247751B2 (en) 2007-07-24
KR20070088485A (ko) 2007-08-29
JP2008507565A (ja) 2008-03-13

Similar Documents

Publication Publication Date Title
US7247751B2 (en) Processes for preparing cinacalcet hydrochloride crystal Form I
ES2797124T3 (es) Cristales
ES2293993T3 (es) Inhibidores de produccion de tnf-alfa.
ES2750676T5 (en) Crystalline dihydrochloride hydrate salt of omecamtiv mecarbil and process for its preparation
JP2008507566A6 (ja) シナカルセト塩酸塩結晶フォームｉの調製方法
JP5513660B2 (ja) 結晶の差異評価への表面自由エネルギーの使用、表面自由エネルギーを指標として評価される結晶及び該結晶を含有してなる医薬組成物
RU2643802C2 (ru) НАТРИЕВАЯ СОЛЬ 5-БРОМ-2-(α-ГИДРОКСИПЕНТИЛ)БЕНЗОЙНОЙ КИСЛОТЫ В РАЗЛИЧНЫХ КРИСТАЛЛИЧЕСКИХ ФОРМАХ И СПОСОБЫ ЕЕ ПОЛУЧЕНИЯ
JPH07501330A (ja) 新規な置換されたサリチル酸
RS65137B1 (sr) Farmaceutski preparat koji obuhvata antivirusno efikasan derivat dihidrohinazolina sa s konfiguracijom u položaju 4
BR112013008054B1 (pt) Composição e processo para produção de sal de acetato de fenil l-ornitina
BRPI0718546A2 (pt) Formas cristalinas de hemifumarato de alisquireno
CN109776430B (zh) 一种磺胺二甲嘧啶共晶及其制备方法
CN115385893A (zh) 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法
ES2314593T3 (es) Forma cristalina alfa de ranelato de estroncio, su procedimiento de preparacion y composiciones farmaceuticas que la contienen.
ES2909709T3 (es) Inhibidores del receptor 2 activado por proteasa
ES2864277T3 (es) Sal de compuestos de ácido dicarboxílico
CN104628677A (zh) 一种沃替西汀有机酸盐晶型及其制备方法
JP4156795B2 (ja) アミノアルカンスルホン酸、ホスホン酸およびホスフィン酸の新たな誘導体、それらの製造、並びに薬物としてのそれらの使用
CN104356038A (zh) 维生素d2与d3的共晶及其制备方法和用途
ES2356838T3 (es) Base cristalina del escitalopram y comprimidos orodispersables que comprenden la base del escitalopram.
ES2928785T3 (es) Sal de edaravona
JP2008526836A (ja) シブトラミンの無機酸塩
BR112020010803A2 (pt) sal, (r)-3-(1-(2,3-dicloro-4-(pirazin-2-il)fenil)-2,2,2-trifluoroetil)-1-metil-1-(1-metilpiperidin-4-il) uréia cristalino, produto de medicamento, composição, método para preparar o sal e usos do sal
WO2012139524A1 (zh) 具有光学活性的低毒性cb1受体抑制剂及其制备方法和用途
RS59349B1 (sr) Soli nalmefena kao lekovi za smanjenje konzumiranja alkohola ili za sprečavanje prekomernog konzumiranja alkohola